loader image

FOLLICLE-ECM PRIME™ | Support of scalp hair growth and density in androgenetic alopecia (AGA)

Scorecard >90: Metodology Q-REVEL+®

Intellectual Property: Protected, with usage rights granted to licensed parties under contract. Unauthorized use is subject to legal penalties.

Technical-Educational Program + Detailed Technical-Scientific Report of the Candidate Program Licensed (digital delivery for educational use and licensing).

Licensing Agreement: Commercial use of the candidate program, including its formulations, designs and bioactive concepts, requires a licensing agreement that defines exclusivity terms, royalties and intellectual property rights. This agreement ensures that the program is used in a legally compliant and safe manner, respecting the innovations and proprietary know-how of the licensor.

Loading...

Descrição

1. Asset overview

FOLLICLE-ECM PRIME™ is a scalp-focused candidate program designed as a topical platform to support hair density and scalp microenvironment in adult men and women with mild to moderate pattern hair thinning, with emphasis on perifollicular extracellular matrix (ECM), anagen support, and control of local low-grade inflammation and oxidative stress.

The asset is presented as a technical development dossier (Wet-Lab + CMC + QbD), providing an integrated view from biological rationale to product concept, formulation route, analytical strategy, stability approach, safety summary, clinical outline and high-level regulatory positioning for a topical hair-thinning support product.

Table 1 – Asset overview

Item Description
Asset name FOLLICLE-ECM PRIME™
Category Candidate Program Licensed
Nature Topical ECM / pro-anagen scalp platform
Functional focus Support for hair density and scalp microenvironment in mild–moderate pattern hair thinning
Use segment Technical program and topical product development for adult men and women

2. Biological rationale and functional target

FOLLICLE-ECM PRIME™ is centered on a multi-module approach to hair thinning, integrating perifollicular ECM, follicle cycling and the scalp niche (inflammation, oxidative stress, barrier).

Perifollicular ECM and fibrosis

The asset is designed around the concept that:

  • Perifollicular fibrosis and ECM stiffening can mechanically constrain miniaturized hair follicles and reduce their ability to produce thicker hairs;
  • Modulating ECM quality may help create a more compliant environment around the follicle, compatible with healthier cycling and better hair anchoring;
  • An ECM-oriented axis complements strategies that act primarily through androgens or vasodilation.

Anagen support and hair density

The program incorporates a pro-anagen dimension:

  • Support for anagen duration and transition from telogen to anagen is treated as central to visible hair density;
  • Selected actives are oriented to hair shaft diameter, proportion of thicker hairs and overall hair counts in thinning areas;
  • The overall design is compatible with long-term daily use in mild to moderate pattern hair thinning in adults.

Scalp microenvironment (inflammation, oxidative stress, barrier)

The asset also addresses the “follicular niche”:

  • Chronic low-grade inflammation and oxidative stress are recognized contributors to progressive thinning and scalp discomfort;
  • Barrier and hydration status of the scalp are considered part of a stable microenvironment for follicle health;
  • Topical support includes calming, antioxidant and barrier-related pathways within a profile suitable for OTC-style use.

Complementarity to conventional approaches

In this framework, FOLLICLE-ECM PRIME™ is positioned as:

  • A complementary option to conventional topical hair-thinning products, with emphasis on ECM and microenvironment rather than a single mechanism;
  • Potentially usable alongside existing regimens under professional guidance, according to local practice and labelling;
  • A candidate for chronic daily application on intact scalp skin in adult men and women.

3. Technological concept

Core physicochemical and vehicle features

FOLLICLE-ECM PRIME™ is designed as a low-viscosity topical lotion:

  • Oil-in-water type vehicle suitable for leave-on scalp application;
  • Hydroalcoholic and aqueous components adjusted for spreadability and comfortable drying time;
  • Suitable for spray or precision applicator formats, with a light sensorial profile for routine daily use;
  • A stability approach compatible with controlled pH, solvent ratio and excipient selection.

These characteristics support the development of scalp-directed topical forms with cosmetic-grade sensorial attributes and OTC positioning potential.

Application strategy and use pattern

The application strategy is built around:

  • Use on intact scalp skin, typically once or twice daily, according to the final product label;
  • Targeted application to thinning areas while allowing adequate diffusion over the scalp surface;
  • Compatibility with common hair care routines (shampoos, conditioners) when spaced appropriately.

API and finished product engineering (high level)

The technical concept includes:

  • Standardized active fractions oriented to ECM modulation, follicle support and microenvironment control;
  • Quality expectations for raw materials, including identity, purity and microbiological suitability for topical use;
  • Base process steps for lotion manufacture, with attention to order of addition, mixing and temperature;
  • Analytical strategies focused on identity, content uniformity, appearance and basic performance and stability endpoints.

4. Potential positioning axes for the product

Based on the mechanistic and translational synthesis, FOLLICLE-ECM PRIME™ supports different positioning axes for a single product or line, depending on strategy and regulatory context.

Table 2 – Example positioning axes

Use axis Value proposition Suggested target population
Unisex pattern hair thinning Support for hair density and appearance of thinning areas Adult men and women with mild–moderate pattern hair thinning
ECM / scalp structure focus Topical support oriented to perifollicular ECM and scalp structure Users seeking mechanisms that go beyond conventional monotherapies
Adjunct to existing regimens Complementary option alongside established topical or systemic routines Individuals under professional supervision for hair-thinning management
Scalp microenvironment care Care of the scalp niche (comfort, barrier, local oxidative stress) Adults with thinning hair and scalp sensitivity or dryness

5. Differentiators versus conventional protein supplementation

Mechanistic clarity
Integrated focus on perifollicular ECM, follicle cycling and scalp microenvironment, building a coherent narrative that goes beyond a single-target approach typically used in conventional topical products.

High functional density at the site of action
Design oriented to delivering actives directly to the scalp and follicular region with a light, leave-on vehicle suitable for long-term routines.

Convenience and cosmetic compatibility
Low-viscosity lotion compatible with daily hair care, minimizing impact on hairstyle and routine when properly integrated.

Clinical and practical integration
Concept suitable for incorporation into comprehensive hair-thinning strategies, from cosmetic positioning to OTC-style regimens, according to local regulation and professional guidance.

6. Structure of the technical program

The FOLLICLE-ECM PRIME™ dossier is organized as a structured program that can be used as a technical backbone for development.

Table 3 – Main components of the FOLLICLE-ECM PRIME™ technical program

Component Main content (summary)
Scientific foundation Pathophysiology of pattern hair thinning, ECM and scalp niche, translation to topical concept
Physicochemical profile Key properties of the vehicle and actives, and implications for formulation and control
Delivery strategy Topical application objective, scalp distribution and proposed dosage forms
API section Overview of standardized fractions, qualification and high-level specifications
Product engineering High-level process description and formulation space for the lotion
Analytical methods Identity, basic assay, appearance and performance-related tests
Stability and packaging Stability approach and recommended packaging concepts compatible with the vehicle
Safety and preclinical basis Summary of topical safety considerations and supportive data overview
Pilot human study (concept) Outline of proof-of-concept design for hair density and scalp-related endpoints
Clinical–product integration Key performance indicators linking biology, formulation and user-level outcomes
Regulatory route (overview) Recommended OTC or cosmetic / drug–cosmetic positioning, depending on market
Development roadmap Suggested sequence for Wet-Lab, CMC, basic clinical and regulatory activities
CQAs and risk analysis High-level CQAs and qualitative risk / mitigation view for development
Final positioning Integrated positioning statement based on the assembled evidence set

7. Intended regulatory classification

For commercial use, FOLLICLE-ECM PRIME™ is intended to support the development of:

  • Topical products for adults with hair thinning, positioned as OTC or as cosmetic / drug–cosmetic hybrids in line with local rules;
  • Formulations that respect local ingredient lists, topical-use restrictions, labelling formats and scalp-product warnings;
  • Claim sets expressed in structural and functional language, avoiding explicit disease treatment wording.

Examples of conservative claims (to be adapted to local regulations) include:

  • Helps support the appearance of hair density in areas of visible thinning;
  • Supports the scalp environment associated with fuller-looking, healthier-looking hair.

8. Professional statement on use and development

FOLLICLE-ECM PRIME™ is presented as a development asset intended for qualified technical teams in:

  • R&D and formulation,
  • Quality and CMC,
  • Clinical development,
  • Regulatory and medical / scientific affairs focused on dermatology and hair care.

Moving from concept to marketed product involves, under the responsibility of the licensee’s technical team:

  • Defining dosage form, final composition and sensorial profile;
  • Conducting compatibility, performance and stability studies on the selected formulation;
  • Qualifying analytical methods and setting specifications consistent with the target category;
  • Planning regulatory submissions or notifications according to the chosen positioning and markets;
  • When relevant, executing pilot and larger-scale clinical studies aligned with intended claims and strategy.

The asset is not intended for direct use by end consumers and does not, by itself, constitute a finished product. It provides a scientific and technological framework to accelerate the design, evaluation and launch of a topical product based on FOLLICLE-ECM PRIME™, while maintaining alignment with regulatory boundaries for scalp and hair-thinning products.

FOLLICLE-ECM PRIME™ Exclusive Licensing & Exploitation Rights

Topical ECM / pro-anagen scalp platform for hair-thinning support • Technical–educational program, full candidate dossier and exclusive exploitation rights for commercial development.

One-time exclusive licensing and exploitation fee
no royalties • no milestone payments

US$ 125,000

This one-time fee grants exclusive rights to explore and commercialize the FOLLICLE-ECM PRIME™ candidate program, including development, registration and commercialization of one or more topical scalp products based on FOLLICLE-ECM PRIME™, as defined in the licensing agreement.

There are no ongoing royalties and no milestone payments under this base license. After payment, our team will contact you using the Stripe billing details to finalize the exclusive licensing agreement and release the complete technical dossier, program content and exploitation documentation under the agreed terms.


Proceed to Secure Stripe Checkout

Technology Readiness Level of our Candidate Programs

We position our candidate programs as TRL 3 technology in the classical TRL 1–9 scale: experimental proof-of-concept, with structured biology, mechanisms and decision trails that can be extended by independent R&D, clinical and regulatory teams.

At this level, the program delivers a scientifically auditable starting point – not a finished clinical or commercial product. It organizes hypotheses, variables, biomarkers and endpoints in a way that reduces uncertainty and accelerates downstream lab, prototype and regulatory work.

Technology Readiness Levels (TRL 1–9)
Current position: TRL 3 – Experimental PoC
1
Basic principles
2
Concept formulated
3
Experimental PoC
4
Lab validation
5
Relevant env. tests
6
Prototype in use
7
System demo
8
Qualified system
9
Full deployment
TRL 3 – candidate programs and experimental proof-of-concept
TRL 1–2 – fundamental science and conceptual exploration
TRL 4–6 – laboratory, pilot and prototype validation
TRL 7–9 – regulatory-grade systems and market deployment

Innovation Engineering Applied to Biotechnology

Categorias